IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.
about
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsClinical manufacturing of CAR T cells: foundation of a promising therapyChimeric Antigen Receptors Modified T-Cells for Cancer TherapyAdoptive T-cell therapy for cancer: The era of engineered T cellsCD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic LeukaemiaEngineering cord blood to improve engraftment after cord blood transplant.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Novel Immunotherapies for Multiple Myeloma.Emerging immunotherapy in pediatric lymphoma.Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications.Advances in umbilical cord blood cell therapy: the present and the future.A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cellsThe future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.Engineered T cells: the promise and challenges of cancer immunotherapy.Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Anticancer cellular immunotherapies derived from umbilical cord blood.Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT.Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.CAR T-cell therapy: opportunities and challenges.Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.
P2860
Q26741260-3D9EF624-CC69-4A79-84D8-CC6464574897Q26747037-787AD6E6-9E0F-48E1-A024-8FF5F9167525Q26773309-DD0E6FB9-9350-43F7-9C3A-F55568CFBF89Q26800611-C9564D9A-CBA5-438D-8205-DB9645B21416Q28081600-3F0ADA41-F168-48CD-90A1-F204B10242B5Q33766995-1FBA2871-1519-4D80-BD6E-2ED47BB18985Q34517676-E1596AF9-4E78-45F0-B61A-96CB4C9FF6FCQ35980893-2CD5A53D-E017-4E54-A81D-C6B8536C761DQ38525024-DE619385-F0C5-457D-8A0F-A59BE67AE62BQ38640444-AA22D09E-2A7F-4FAA-A958-54C43560A62FQ38652326-E0A8F2BC-0ED6-4953-A1A5-C82E94145B4AQ38658670-D4E6C48C-AA00-40D3-8560-86C35890CE8CQ38734758-429A717B-89A9-48BE-8804-8888D53472FFQ38766349-8FA2111C-DA03-4C41-AEBC-BA98C9AF3445Q38775177-A801651C-0879-4A6C-B781-19452BD8207EQ38787449-A241CEAC-1410-4F96-9ED9-FC2732F644C5Q38828829-2D52B2BD-1914-4EA1-B71E-87B4E5898B0FQ38873430-916B4AC4-7EC2-49DB-8D50-FE206B5462EBQ38890450-9BACF2BC-FE36-4A98-8E93-7ABA1113542EQ38945853-AE0A3E62-9106-4216-B797-EEA974286439Q39194733-AF4F74D9-7FF6-4F48-B0E0-6BF88639548CQ40973052-B7FC2901-8FD2-4E2C-9423-6A53818DA1ACQ41925180-2DA8EE6F-AFC2-47F9-9135-3811638615C7Q47565827-C7A012B7-9BE4-4A96-AD7C-A1423EBA0397Q47657491-B2D80446-AC82-4531-90F4-EB028D0FA13EQ47865655-71498F6A-9B77-45CE-A768-B74CFA1310DFQ48192887-807212C3-5AD0-4766-84A8-D482787605B1Q50027149-50B8DA92-94E9-4824-834B-1F9EC783E0B0Q50043438-3A0B30E9-35D0-4FAD-839B-0C556C00E7D8Q54965277-34A57183-2D64-4CDF-8595-A4374A7295BDQ55378779-1B6CC257-1F7F-4326-A65B-3A095514D3D1
P2860
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 July 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
IL-12-secreting CD19-targeted ...... acute lymphoblastic leukemia.
@en
IL-12-secreting CD19-targeted ...... acute lymphoblastic leukemia.
@nl
type
label
IL-12-secreting CD19-targeted ...... acute lymphoblastic leukemia.
@en
IL-12-secreting CD19-targeted ...... acute lymphoblastic leukemia.
@nl
prefLabel
IL-12-secreting CD19-targeted ...... acute lymphoblastic leukemia.
@en
IL-12-secreting CD19-targeted ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P356
P1433
P1476
IL-12-secreting CD19-targeted ...... acute lymphoblastic leukemia.
@en
P2093
D G van Leeuwen
H J Pegram
J N Barker
K J Curran
R J Brentjens
S A Giralt
P2860
P2888
P304
P356
10.1038/LEU.2014.215
P577
2014-07-09T00:00:00Z
P6179
1017338759